People in the study will receive either VMX-C001 or the usual care used for this situation. Some participants may also receive heparin, another blood-thinning medicine, if planned by the treating team. The study is designed to compare the two approaches during the procedure and shortly afterward, without changing the urgent care needed for the surgery or procedure.

Participants in the study will receive UGN-102 as a primary treatment to see if it can effectively remove the cancer. The study will follow a single-arm design, meaning all participants will receive the same treatment without a comparison group. The treatment period will last for a maximum of six weeks, and the participants will be monitored for any changes in their condition. The study will assess the cancer’s response to the treatment at various points, including three months after the first dose.

Throughout the study, the safety of UGN-102 will be closely monitored by checking for any side effects or adverse reactions. Participants will undergo regular check-ups, including physical exams and laboratory tests, to ensure their well-being. The study aims to provide valuable information on the potential of UGN-102 as a treatment option for patients with low-grade NMIBC, helping to determine if it can effectively reduce or eliminate the cancer while maintaining a good safety profile.

The purpose of the study is to evaluate how effective and safe UGN-103 is in treating this type of bladder cancer. Participants in the study will receive the treatment and will be monitored over a period of time to see how well the cancer responds. The study will involve regular check-ups, including procedures like cystoscopy, which is a way to look inside the bladder, and urine tests to check for cancer cells. The study will also track any side effects or reactions to the treatment to ensure it is safe for patients.

Throughout the study, the main goal is to see if the treatment can successfully remove the cancer and prevent it from returning. Participants will be followed for several months to observe the long-term effects of the treatment. This research aims to provide new insights into treating Nonmuscle Invasive Bladder Cancer and potentially offer a new option for patients with this condition.

The purpose of the study is to evaluate how well these treatments work and how safe they are for patients with these infections. Participants in the study will receive one of the treatment combinations or a placebo, and their progress will be monitored over a period of time. The study will involve regular visits to the clinic for check-ups and assessments to see how the infection is responding to the treatment. The goal is to find out which treatment is most effective in curing the infection and preventing it from coming back.

Throughout the study, participants will be closely observed to ensure their safety and to monitor any side effects that may occur. The study aims to provide valuable information that could help improve the treatment of these types of infections in the future. By comparing the different treatment options, researchers hope to identify the best approach for managing cUTI and AP, ultimately leading to better outcomes for patients.

The purpose of this research is to determine how well oral tebipenem pivoxil works compared to intravenous imipenem-cilastatin in treating these urinary tract infections. The study will measure whether the infections are cured and if the bacteria causing the infections are eliminated. The medications will be given to adult patients who are in the hospital.

During the study, patients will receive treatment for up to 10 days. The study team will monitor patients’ symptoms and take urine samples to check if the infection is responding to treatment. They will also check for any side effects from the medications. After the treatment period ends, patients will have follow-up visits to ensure the infection has been properly treated.

Participants in the study will be randomly assigned to receive either andexanet alfa or the standard treatment, which may include a placebo. The study will monitor the effectiveness of andexanet alfa in controlling bleeding during surgery and will also track changes in the activity of the Factor Xa inhibitors from the start of the surgery to two hours afterward. The study aims to provide valuable information on how well andexanet alfa works in real-world surgical settings.

The trial will involve a series of steps, including the administration of the treatment and careful monitoring of the patient’s condition during and after the surgery. The study is expected to continue until November 2026, with recruitment starting in December 2023. This research is important for improving the safety and effectiveness of surgeries for patients who are on Factor Xa inhibitors and need urgent medical attention.